Viral protein Nef enables a step toward off-the-shelf CAR T cell therapy for cancer
CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...
GEN1d
Making Strides Toward Off-the-Shelf CAR T Cell Therapy for Cancer
A new advance may make it possible to use off-the-shelf CAR T cells provided by healthy donors. The new approach studied in mice equipped CAR T cells with the viral protein Nef.
technologynetworks4d
Study Paves Way for Off-the-Shelf Cancer CAR T-Cell Therapy
The research identifies a way to modify the donor CAR T cells, called allogeneic CAR T cells, so that they won’t be rejected by the patient receiving them and will persist in fighting the cancer. The ...
Targeted Oncology12d
First Dose of CD38-Targeting CAR T-Cell Therapy Administered in AML
The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...
Pharmabiz13d
CARsgen’s allogeneic CD38 CAR-T therapy administers first dose in an investigator-initiated trial
CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumours, announces that KJ-C2320, an allogeneic CAR ...
VectorBuilder Powers FDA IND Approval of World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product
VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...
FiercePharma13d
Atara's Ebvallo and pipeline candidate put on clinical hold in US after partner's failed plant inspection
After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications; Inno ...
Medical Xpress4d
Viral protein Nef enables a step toward off-the-shelf CAR T cell therapy for cancer
The research identifies a way to modify the donor CAR T cells, called allogeneic CAR T cells, so that they won't be rejected by the patient receiving them and will persist in fighting the cancer.
Business Wire5d
VectorBuilder Powers FDA IND Approval of World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product
CHICAGO--(BUSINESS WIRE)--VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug ...